ERBB2 and heart disorder: As cardiotoxicity due to HER2-targeted therapy is well recognized, patients at increased risk for cardiac events are frequently excluded from trials, leaving little evidence for the treatment of patients with baseline cardiac disease, a common scenario in clinical practice.